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Thehepatocytegrowth factor (HGF)/MNNGHOS transforminggene (MET) pathway regulates cell growth, survival, and
migration. MET is mutated or amplified in several malignancies. In myeloma,MET is not mutated, but patients have
high plasma concentrations of HGF, high levels ofMET expression, and gene copy number, which are associatedwith
poor prognosis and advanced disease.Our previous studies demonstrated thatMET is critical formyelomacell survival
and its knockdown induces apoptosis. In our current study, we tested tivantinib (ARQ 197), a small-molecule
pharmacological MET inhibitor. At clinically achievable concentrations, tivantinib induced apoptosis by N50% in all 12
human myeloma cell lines tested. This biologic response was associated with down-regulation of MET signaling and
inhibition of the mitogen-activated protein kinase and phosphoinositide 3-kinase pathways, which are downstream of
the HGF/MET axis. Tivantinib was equally effective in inducing apoptosis in myeloma cell lines resistant to standard
chemotherapy (melphalan, dexamethasone, bortezomib, and lenalidomide) as well as in cells that were co-cultured
with a protective bone marrow microenvironment or with exogenous cytokines. Tivantinib induced apoptosis in
CD138+ plasma cells frompatients and demonstrated efficacy in amyeloma xenograftmousemodel. On the basis of
thesedata,we initiated a clinical trial for relapsed/refractorymultiplemyeloma (MM). In conclusion,MET inhibitorsmay
be an attractive target-based strategy for the treatment of MM.
Neoplasia (2015) 17, 289–300Introduction
Multiple myeloma (MM) is an incurable B-cell disorder characterized
by the accumulation of mature plasma cells producing a monoclonalprotein in the bone marrow [1]. The incidence of myeloma in the
United States is four to five per 100,000 individuals [2]. Even though
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Table 1. List of Human Myeloma Cell Lines
Cell Line Origin Medium + Supplements Characteristics
U266 RPMI-1640 + 10% FBS
OPM-2 RPMI-1640 + 10% FBS
MM.1S Dr Rosen, Lurie
Comprehensive Cancer
Center (Chicago, IL) [36]
RPMI-1640 + 10% FBS Glucocorticoid
sensitive
MM.1R Dr Rosen, Lurie
Comprehensive Cancer
Center (Chicago, IL) [36]
RPMI-1640 + 10% FBS Glucocorticoid
resistant
RPMI-8226 Dr Orlowski, UT MD
Anderson Cancer Center
(Houston, TX) [28,29]
RPMI-1640 + 10% FBS,
1% penicillin-streptomycin,
10 mM L-glutamine
ANBL-6 Dr Orlowski, UT MD
Anderson Cancer Center
(Houston, TX) [28,29]
RPMI-1640 + 10% FBS,
1% penicillin-streptomycin, 10
mM L-glutamine, 1 ng/ml IL-6
Bortezomib
sensitive
ANLB-6/
V10R
Dr Orlowski, UT MD
Anderson Cancer Center
(Houston, TX) [28,29]
RPMI-1640 + 10% FBS,
1% penicillin-streptomycin,
10 mM L-glutamine, 1 ng/ml
IL-6, 10 nM bortezomib
Bortezomib
resistant
KAS-6/1 Dr Orlowski, UT MD
Anderson Cancer Center
(Houston, TX) [28,29]
RPMI-1640 + 10% FBS,
1% penicillin-streptomycin,
10 mM L-glutamine, 1 ng/ml IL-6
Bortezomib and
lenalidomide
sensitive
KAS-6/
V10R
Dr Orlowski, UT MD
Anderson Cancer Center
(Houston, TX) [28,29]
RPMI-1640 + 10% FBS,
1% penicillin-streptomycin,
10 mM L-glutamine, 1 ng/ml
IL-6, 10 nM bortezomib
Bortezomib
resistant
KAS-6/
R10R
Dr Orlowski, UT MD
Anderson Cancer Center
(Houston, TX) [28,29]
RPMI-1640 + 10% FBS,
1% penicillin-streptomycin,
10 mM L-glutamine, 1 ng/ml
IL-6, 10 nM lenalidomide
Lenalidomide
resistant
8226/S Dr Dalton, Moffitt Cancer
Center (Tampa, FL) [25]
RPMI-1640 + 10% FBS Melphalan
sensitive
8226/LR-5 Dr Dalton, Moffitt Cancer
Center (Tampa, FL) [25]
RPMI-1640 + 10% FBS,
5 μM melphalan
Melphalan
resistant
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7 to 8 years [1]. Thus, new targets for drug development are needed
for the treatment of MM.
One target may be hepatocyte growth factor (HGF). In MM, patients
have high serum concentrations of HGF as compared to healthy subjects
[3]. High HGF level in MM patients have been correlated with poor
prognosis [4–6]. Therefore, investigators have targeted HGF with
anti-HGF antibodies or HGF antagonists to treat this disease [7,8].
Additionally, compared to CD138-negative cells, increased copy number
of theMNNGHOS transforming gene (MET) gene aswell as an increase
in MET mRNA levels, which encodes for the HGF receptor, has been
reported in myeloma patients [9]. Furthermore, higher MET levels were
also associated with poor response and survival of myeloma patients
treated with bortezomib-based induction therapy.
TheMET receptor tyrosine kinase is a proto-oncogene that regulates
cell growth, survival, and migration [10,11]. When HGF binds to
MET, it leads to dimerization of MET and phosphorylation of tyrosine
residues in the kinase domain (Y1230, Y1234, and Y1235). This
triggers autophosphorylation of tyrosine residues (Y1349 and Y1356) in
the carboxyl-terminal substrate binding site, resulting in the binding of
effector molecules such as growth factor receptor-bound protein 2,
GRB2-associated-binding protein 1, phospholipase C, and cellular SRC
kinase. The effector molecules activate a signaling cascade that includes
the phosphoinositide 3-kinase/AKT and mitogen-activated protein
kinase (MAPK) pathways, which leads to stimulation of cell
proliferation, survival, and migration [11].
MET knockdown in MM cells by ribozyme or shRNA has
demonstrated thatMET is required for cell survival, and its knockdown
inhibited the growth of myeloma cells and induced apoptosis in these
cells [12,13]. In addition, proof of principal studies targetingMETwith
small-molecule inhibitors such as PHA-665752, SU11274, and
amuvatinib showed efficacy in myeloma cells [14–16]. These studies
suggested that targeting MET could be an effective strategy for treating
MM patients. While shRNA and ribozyme strategies are not clinically
practical and the MET inhibitors, PHA-665752, SU11274, and
amuvatinib, are not clinically viable choices, new small-molecule
inhibitors of MET are being designed and developed.
ARQ 197 (tivantinib) is a small-molecule, non–ATP-competitive
inhibitor of MET. In an in vitro kinase assay, in which ARQ 197 was
tested against a panel of 230 human kinases, it inhibited MET with
high specificity (Ki = 355 nM) [17]. ARQ 197 inhibits MET by
binding to the inactive conformation of MET to stabilize this
conformation [18]. This prevents MET phosphorylation and
dampens downstream signaling, thereby resulting in growth
inhibition and induction of apoptosis in solid tumors [17,19].
Phase I clinical trials of tivantinib have demonstrated activity in primary
andmetastatic solid tumors [7,20]. The maximum tolerated oral dose was
360 mg twice daily. At this dose, a steady-state plasma concentration of 6
to 7 μM was achieved [20]. Phase II investigations with single-agent
tivantinib demonstrated efficacy in solid tumors [21,22]. The combina-
tion of tivantinib and erlotinib has been tested in phase I and II
investigations, and phase III trials are ongoing [23–25]. Both as a single
agent and in combination, tivantinib has beenwell tolerated. Furthermore,
biomarker studies have demonstrated the effectiveness of tivantinib in
inhibiting MET and inducing apoptosis of the target tumor cells [20].
On the basis of the importance of MET in myeloma and the results
of clinical trials with tivantinib in solid tumors, we hypothesized that
this molecule will affect the HGF/MET axis in myeloma cells and
induce cytotoxicity. We used several myeloma model systems andfound that ARQ 197 was highly efficacious in inhibiting growth and
inducing apoptosis even under conditions associated with resistance
to standard myeloma therapies. Additionally, this drug blocked HGF/
MET signaling in these cells and was cytotoxic to primary myeloma
cells. On the basis of these encouraging data, we are testing tivantinib
in a National Cancer Institute Cancer Therapy Evaluation Program–
sponsored phase II clinical trial for patients with relapsed/refractory
MM (NCT01447914).
Materials and Methods
Cell Cultures and Reagents
Twelve human myeloma cell lines were used for the current
investigation (Table 1) [26–29]. These were maintained at 37°C in a
humidified incubator with 5% CO2 and were authenticated and
tested for Mycoplasma infection by The University of Texas (UT)
MD Anderson Cancer Center Characterized Cell Line Core.
Resistant cell lines were maintained as described before
[26,27,29,30]. NKtert human marrow stromal cells (NKtert;
RIKEN Cell Bank, Koyadai, Japan [31]) were maintained as
described previously [32]. Tivantinib (ARQ 197) was obtained
from Active Biochem (Maplewood, NJ) and ArQule (Woburn, MA).
Cell Growth and Survival Analysis
Flow cytometry analysis of annexin V/propidium iodide (PI)
staining as a measure of cell survival was performed as described
before [12]. The effect of ARQ 197 treatment on cell growth was
measured in exponentially growing cells by determining the cell
number using a Coulter counter (Beckman Coulter, Fullerton, CA).
Neoplasia Vol. 17, No. 3, 2015 Targeting MET in Multiple Myeloma Zaman et al. 291Thymidine Incorporation Assay. To measure DNA synthetic
capacity of cells, myeloma cell lines (U266 and OPM-2) were treated
with interleukin 6 (IL-6) or HGF or were placed on stroma. One hour
before harvesting, cells were incubated with 2 μCi [3H]thymidine at
37°C. Cell concentration was measured using a Coulter counter. DNA
synthesis was measured as described before [33].
Western Blot Analysis and Antibodies
Whole-cell lysates were prepared as described before [34].
Immunoblots were scanned and quantitated on an Odyssey imaging
system (LI-COR Biosciences, Lincoln, NE). Antibody information
for all proteins is provided in Supplementary Table 1.
Co-Culturing U266 or OPM-2 Cells with NKtert Cells
To co-culture myeloma (U266, OPM-2) cells with bone marrow
stromal cells, NKtert cells were seeded in 12-well plates at 2.5 ×
104 cells/ml. After 16 to 18 hours, myeloma cells were seeded at 5 ×
105 cells/ml in RPMI-1640 medium supplemented with 10% FBS.
Cells were co-cultured for 2 hours before treatment was initiated.
Forty-eight hours later, myeloma cells, which are suspension cells,
were removed for analysis without disturbing the adherent NKtert
cells. Attached stromal cells were harvested by detaching with
Accutase Cell Detachment Solutions (Innovative Cell Technologies,
San Diego, CA) and similarly assessed.
Bone Marrow Samples and Isolation of CD138+ Cells
Bone marrow samples were collected from 15 patients with
myeloma through a protocol approved by the MD Anderson Cancer
Center Institutional Review Board and in accordance with the
Declaration of Helsinki. Cells were cultured in RPMI-1640 medium
supplemented with 10% FBS at 37°C in a humidified incubator with
5% CO2 for 72 hours with or without ARQ 197. CD138+ fraction
was isolated from bone marrow for 10 patient samples at the MD
Anderson Myeloma Core as described before [27]. For the other five
patients, cells were obtained unsorted. These samples were stained
with 10 μl of CD138-APC (Miltenyi Biotec, Auburn, CA) for 10
minutes just before processing for annexin V/PI staining for flow
cytometry analysis.
Flow Cytometry Analysis of MET and Phospho-MET
CD138+ plasma cells were isolated from bone marrow of MM
patients. Cells were fixed and permeabilized with BD cytofix/
cytoperm fixation and permeabilization solution kit (BD Biosciences,
San Jose, CA). For detection of phospho-MET, cells were incubated
with phospho-MET(Y1234/1235) for 30 minutes at room temperature
followed by a wash with 1× BD Perm/Wash Buffer. Control cells were
incubated with normal rabbit IgG. Next, cells were incubated with
secondary antibody (goat anti-rabbit IgG-phycoerythrin) for 30 minutes
at 4°C. Cells were washed with 1× BD Perm/Wash Buffer and analyzed
by flow cytometry.
For detection of total MET, cells were incubated with anti-human
HGF R/c-MET-fluorescein or normal mouse IgG1–fluorescein
isothiocyanate (for control cells) for 30 minutes at room temperature,
washed with 1× BD Perm/Wash Buffer, and analyzed by flow
cytometry. Antibody information is provided in SupplementaryTable 1.
Murine Xenograft Model of Myeloma
All mice procedures were conducted through a protocol approved by
the UT MD Anderson Cancer Center Institutional Animal Care and
Use Committee. Six- to eight-week-old severe combined immunode-ficient mice (BALB/c background; National Cancer Institute Frederick
Laboratory for Cancer Research, Frederick, MD) were subcutaneously
injected once into the right flank with 2 × 106 MM.1S cells. When a
tumor reached 0.5 mm in the longest dimension, the mouse was
randomly placed in the vehicle (control) group or the ARQ 197–treated
group. Mice were treated as described before [17]. Tumor volume was
calculated with the formula: (width2 × length × π)/6.
Statistical Analysis
Data were analyzed and graphed using GraphPad Prism
(GraphPad software version 6, San Diego, CA). The statistical
analyses used are indicated in the respective sections.
Results
ARQ 197 Inhibited Cell Growth and Induced Cell Death in
Myeloma Cell Lines
To investigate the effect of ARQ 197 on the growth of myeloma
cells, we treated U266, MM.1S, OPM-2, and RPMI-8226 cells with
increasing doses of ARQ 197. Compared to control treatment,
dose-dependent inhibition of cell growth increased notably at 1 μM
ARQ 197 in all four cell lines (46%, 33%, 29%, and 48%,
respectively; Figure 1A). At 3 μM ARQ 197, cell growth was
inhibited even further for all cell lines. There was a corresponding
increase in cell death as measured by an increase in annexin V/PI
staining and detection of procaspase-3 cleavage. At 1 μM ARQ 197,
the percentage of dead cells increased by 54% in U266, 25% in
MM.1S, 18% in OPM-2, and 58% in RPMI-8226 cell lines
compared with the DMSO-treated cells (Figure 1B). In all the cell
lines, 3 μM ARQ 197 induced N70% cell death. Consistent with the
cell death data, ARQ 197 treatment increased procaspase-3 cleavage
in a dose-dependent manner (Figure 1C). The half maximal
inhibitory concentration (IC50) for cell death for these cell lines
ranged from 0.9 to 1.8 μM (RPMI-8226 = 0.9 μM, U266 = 1.1 μM,
MM.1S = 1.6 μM, OPM-2 = 1.8 μM). This IC50 range was well
below the steady-state plasma concentration of 6 to 7 μM that is
achievable in the clinic, suggesting that ARQ 197 can effectively
target myeloma cells in patients [20]. In addition, a time-dependent
increase in annexin V/PI positive cells was observed in U266 and
MM.1S cells with both 1 and 3 μM ARQ 197 (Figure 1, D and E).
These data demonstrated that ARQ 197 induced cell death in
myeloma cell lines in a dose- and time-dependent fashion.
ARQ 197 Overcame Microenvironment-Mediated Drug
Resistance and Induced Cell Death in Myeloma Cell Lines
The bone marrow microenvironment is a major source of drug
resistance for myeloma cells. It produces cytokines such as HGF and
IL-6, which stimulate the growth of myeloma cells and contribute to
their resistance to treatment [35]. HGF and, to some extent, IL-6
stimulated DNA synthesis in U266 and OPM-2 cells (Supplementary
Figure 1, A and B). To determine whether ARQ 197 overcomes the
protection conferred by the bone marrow microenvironment, we
treated U266 and OPM-2 cells with 3 μMARQ 197 in the presence of
high concentrations of exogenous IL-6 or HGF for 48 hours. ARQ 197
inhibited cell growth in the presence of IL-6 or HGF to a similar extent
as treatment with ARQ 197 alone (Figure 2, A and C). In U266 cells,
compared with DMSO-treated cells, 3 μM ARQ 197 significantly
inhibited growth in the presence of 50 ng/ml IL-6 (60% inhibition, P b
.0001) or 50 ng/ml HGF (64% inhibition, P b .0001). Similarly, in
OPM-2 cells, 3 μMARQ 197 significantly inhibited growth compared
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Figure 1. ARQ 197 inhibited cell growth and induced cell death in myeloma cell lines. (A) Myeloma cell lines (U266, MM.1S, OPM-2, and
RPMI-8226) were incubated with DMSO or 0.03, 0.1, 0.3, 1, or 3 μM ARQ 197 for 48 hours. Cell concentration was measured. Data are
displayed as percentage control. ****P b .0001 versus DMSO by one-way analysis of variance (ANOVA), ***P = .0002 versus DMSO by
one-way ANOVA. (B) Cells used in A were stained for annexin V–fluorescein isothiocyanate and PI and analyzed by flow cytometry. Data
are displayed as percentage cell death. ****P b .0001 versusDMSO by one-way ANOVA, ***P= .0007 versusDMSO by one-way ANOVA.
(C) U266 cells were serum starved in 0.1% FBS for 8 hours, followed by incubation with 0, 0.3, 1 and 3 μM ARQ 197 for 16 hours. Cell
lysates were prepared after treatment with 50 ng/ml HGF for 15 minutes. Immunoblots were analyzed for caspase-3 and GAPDH. U266
(D) and MM.1S (E) cells were incubated with DMSO or 1 or 3 μMARQ 197 for 2, 12, 24, 48, and 72 hours. The percentage of annexin V/PI
stained cells was measured by flow cytometry. ****P b .0001 versusDMSO by one-way ANOVA, for MM.1S, 1 μMARQ 197, **P= .0026
versus DMSO by one-way ANOVA, ***P = .0002 versus DMSO by one-way ANOVA, for MM.1S, 3 μM ARQ 197, **P = .0084 versus
DMSO by one-way ANOVA. (A, B, D, and E) Data represent mean ± SEM, n = 3.
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.0001) or 50 ng/ml HGF (61% inhibition, P b .0001). Consistent with
the growth inhibition results, incubation with ARQ 197 resulted in
inhibition of cell survival in both U266 and OPM-2 cells in the
presence of these growth factors (Figure 2, B and D).
To further investigate the impact of the microenvironment on drug
resistance, we co-cultured U266 or OPM-2 cells with human NKtert
stromal cells, which provide conditions similar to the bone marrow
microenvironment. Myeloma cells were seeded on NKtert at a
concentration 20× that of NKtert cells. Under these conditions,
NKtert cells stimulated DNA synthesis in U266 cells and, to some
extent, in OPM-2 cells (Supplementary Figure 1C). Forty-eight hours
of treatmentwith 3μMARQ197 resulted in cell death of 54% inU266
cells (Figure 2E) and 69% inOPM-2 cells (Figure 2F) when co-cultured
with NKtert cells; these values were similar to that of U266 cells
cultured alone (55%annexinV+/PI+ cells; Figure 2E) andOPM-2 cells
cultured alone (82% annexin V+/PI+ cells; Figure 2F). Importantly,
ARQ197 did not induce a notable increase inNKtert cell death (22%at
3 μM), suggesting that ARQ 197 spares normal stromal cells.Activity of ARQ 197 in Melphalan- and Dexamethasone-
Resistant Cell Lines
Melphalan is an alkylating agent that was one of the earliest
treatments introduced for myeloma. We tested ARQ 197 on paired
cell lines that were melphalan resistant (8226/LR-5) and melphalan
sensitive (8226/S). ARQ 197 inhibited cell growth by 54% at 3 μM
in 8226/S cells (Figure 3A). This was associated with 77% cell death
(Figure 3B). Despite the melphalan-resistant 8226/LR-5 cells having
a high percentage of endogenous cell death (44%), 3 μM ARQ 197
was still able to inhibit cell growth by 54% and induced 98% cell
death (Figure 3, A and B). The correlation in cell death was high
between 8226/S and 8226/LR-5 cells in their response to ARQ 197
(Pearson correlation 0.8718, P = .0105).
Dexamethasone is another approved agent for myeloma treatment.
Hence, we tested both MM.1R cells, which are resistant to the
synthetic steroid dexamethasone, and MM.1S cells, which are
sensitive, to determine whether ARQ 197 can induce cell death in
these cell lines. At 1 and 3 μMARQ 197, cell growth was inhibited by
33% and 49%, respectively, in sensitive cells and by 28% and 44%,
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Figure 2. ARQ 197 overcame bone marrow microenvironment-mediated drug resistance. (A) U266 cells were treated as indicated for 48
hours. Cell concentration was measured. Data are displayed as cell number (percentage of control). (B) Viable cells were measured by
flow cytometry of annexin V/PI staining. Data are displayed as percentage survival. (C) OPM-2 cells were treated as in A and cell
concentration was measured. Data are displayed as cell number (percentage of control). (D) Viable cells were measured by flow
cytometry of annexin V/PI staining. Data are displayed as percentage survival. (E) U266 cells were incubated with 0, 1, or 3 μM ARQ 197
for 48 hours, either in suspension or co-cultured with NKtert cells. For control experiments, NKtert cells were incubated with 1 or 3 μM
ARQ 197 for 48 hours. Data are displayed as percentage cell death. (F) OPM-2 cells were treated as in (E). Data are displayed as
percentage cell death. (A–E) Data represent mean ± SEM of three biologic replicates. **P = .0011, ***P = .0002, ****P b .0001 versus
DMSO by one-way ANOVA.
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inhibition data, an increase in cell death was detectable with 3 μMARQ
197 andwas similar in both cell lines (Figure 3D). The correlation in cell
death was high between MM.1R and MM.1S cells in their response to
ARQ 197 (Pearson correlation 0.9741, P = .0010).
Activity of ARQ 197 in Cells Resistant to Bortezomib
or Lenalidomide
Newly approved drugs for myeloma include proteasome inhibitors
such as bortezomib and immunomodulatory drugs such as
thalidomide or lenalidomide. However, patients acquire resistance
to these drugs. We examined two pairs of cell lines that were either
sensitive or resistant to bortezomib (ANBL-6 vs ANBL-6/V10R and
KAS-6 vs KAS-6/V10R). In these cell lines, growth inhibition wasobserved starting with 0.3 μM, and by 3 and 10 μM, 50% inhibition
was achieved in both sensitive and resistant cell lines (Figure 4, A and
C). This finding was consistent with that of induction of cell death
(Figure 4, B and D), which was also similar in sensitive and resistant
cell lines. Both paired cell lines exhibited high correlation in their
response to ARQ 197 (Pearson correlation 0.9844, P b .0001
between ANBL-6 and ANBL-6/V10R and Pearson correlation
0.9898, P b .0001 between KAS-6 and KAS-6/V10R).
Finally, a cell line that was resistant to lenalidomide (KAS-6/R10R)
was tested for sensitivity to ARQ 197. Cell growth was inhibited and
cell death was induced by more than 50% at 1 μM ARQ 197 in this
cell line (Figure 4, C and D). ARQ 197–induced cell death was
similar between KAS-6/1 and KAS-6/R10R cells (Pearson correlation
0.9584, P = .0007). These results suggested that ARQ 197 is able to
μ μ
μ μ
A B
C D
Figure 3. ARQ 197 induced apoptosis in melphalan-resistant cells (8226/LR-5) and in dexamethasone-resistant cells (MM.1R). (A and B)
8226/S and 8226/LR-5 cells were treated as indicated for 48 hours, after which cell number (percentage control) (A) and percentage cell
death (B) were measured. (C and D) MM.1S and MM.1R cells were incubated with indicated treatments for 48 hours, and cell number (C)
and cell death (D) were measured. (A–D) Data for MM.1R and MM.1S cells are presented as mean ± SEM, n = 3. Data for 8226/LR-5 are
presented as mean ± SEM. Data for 8226/S cells are presented as mean ± range performed in duplicate.
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or lenalidomide and can inhibit the growth of myeloma cells.
ARQ 197 Inhibited the MET Signaling Pathway
To elucidate the mechanism of ARQ 197–mediated cytotoxicity, we
examined theMET signaling pathway inOPM-2, KAS-6/1, and KAS-6/
R10R cells. For OPM-2, the cells were serum starved for 24 hours in
0.1% FBS and then treated with ARQ 197 for 6 hours (Figure 5A and
Supplementary Figure 2A) or serum starved in 0.1% FBS and treated
with ARQ 197 for 24 hours (Figure 5B and Supplementary Figure 2B).
MET signaling was examined after stimulation with HGF for 15
minutes. As shown in Figure 5, A and B, although these cells showed an
HGF-dependent increase in phosphorylation of MET, ARQ 197
treatment decreased levels of this phosphorylation in a dose-dependent
manner. In addition, total MET levels decreased with ARQ 197
treatment even though glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) levels did not decrease dramatically. These findings are
consistent with an earlier study of ARQ 197 that demonstrated
drug-enhanced MET degradation [36]. We also observed that decreases
in phospho-MET and total MET were associated with decreases in
phospho-AKT (S473). At high concentrations of ARQ 197 (≥1 μM
ARQ 197), total AKT levels also decreased, as has been observed
previously with other MET inhibitors [15]. MET inhibition alsodecreased phospho-glycogen synthase kinase-3 (GSK-3β)(S9) levels, thus
inhibition of the MET downstream signaling pathway. These molecular
events were associated with an increase in the levels of cleaved poly
(ADP-ribose) polymerase (PARP), a target of executioner caspase-3,
indicating the induction of apoptosis. ARQ 197–mediated decrease in
MET signaling was also observed in OPM-2 cells treated with ARQ 197
for 24 hours (Figure 5B and Supplementary Figure 2B).
Immunoblot analysis of KAS-6/1 cells treated with ARQ 197 in
serum-starved media (0.1% FBS) produced similar results as in OPM-2
cells. Treatment of cells with HGF increased the levels of phospho-M-
ET(Y1234/1235) (Figure 5C and Supplementary Figure 2C). This
increase in phospho-protein level did not occur when cells were incubated
with ARQ 197 before HGF stimulation. The decrease in phospho-M-
ET(Y1234/1235) was associated with the decrease in downstream MET
signaling targets such as phospho-AKT(S473), phospho-GSK3β(S9), and
phospho-extracellular-signal-regulated kinases 1/2(T202/204).
To compare the effects of ARQ 197 on both HGF-dependent
MET signaling and signaling in the presence of full serum,
lenalidomide-resistant KAS-6/R10R cells were treated with ARQ
197 for 16 or 24 hours, in the absence or presence of serum,
respectively. Similar to the OPM-2 cells, ARQ 197 treatment
inhibited HGF-dependent phospho-MET (Y1349) with a corre-
sponding decrease in the downstream MET signaling targets and an
μ μ
μ μ
A B
C D
Figure 4. ARQ 197 inhibited cell growth and induced apoptosis in bortezomib-resistant cells and lenalidomide-resistant cell line. Wild-type
ANBL-6 and KAS-6/1 cell lines, bortezomib-resistant cell lines (ANBL-6/V10R and KAS-6/V10R), and a lenalidomide-resistant cell line
(KAS-6/R10R) were incubated with ARQ 197 for 48 hours. (A and C) Cell number wasmeasured. Data are displayed as% control. (B and D)
Apoptosis was measured by flow cytometry after staining with annexin V and PI. Data are displayed as percentage cell death and (A–D)
are presented as mean ± SEM of three replicates.
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(Figure 5D and Supplementary Figure 2D). As expected, in the presence
of full serum, ARQ 197 inhibited phospho-MET(Y1349) levels. In
addition, as expected, the steady-state phosphorylation (thus, signaling)
levels of the various downstream signaling molecules in the untreated
cells in the presence of full serumwas lower than in theHGF-stimulated
cells. Interestingly, despite the presence of other growth factors in the
full serum to induce signaling, ARQ 197 treatment was able to further
reduce AKT, ERK1/2, and GSK3β phosphorylation. This may be
indicating that a significant amount of cellular signaling through AKT
andMAPK pathways inMM cells is induced byMET activity. Overall,
the results demonstrate that the inhibition of MET activity with ARQ
197 inhibited the MET signaling pathway, leading to inhibition of cell
growth and induction of cell death.
ARQ 197 in CD138+ Plasma Cells from Myeloma Patients
and in Murine Xenograft Model of Myeloma
To extend the cell line data to primary myeloma plasma cells,
CD138+ cells obtained from 15 patients with myeloma were treated
with 10 μM ARQ 197 for 72 hours and annexin V/PI stained cells
were analyzed by flow cytometry. CD138+ cells treated with 10 μM
ARQ 197 demonstrated statistically significant increase in annexin V/PI
positivity compared to control cells (P b .05 by unpaired t test;
Figure 6A). These results indicated that ARQ 197 reduced viability ofprimary myeloma samples. Treatment of CD138+ plasma cells
with ARQ 197 was associated with decreased levels of phospho-MET
(Y1234/1235) (Figure 6B). The geometric mean decreased from 32.3 to
28.9 for patient 44, 32.2 to 25.7 for patient 45, and 54.1 to 41.1 for
patient 46 upon treatment with 10 μM ARQ 197. Total MET levels
(Figure 6C) also decreased upon ARQ 197 treatment (9.04 to 6.81 in
patient 44, 8.95 to 7.84 in patient 45, and 6.30 to 5.25 in patient 46).
These data demonstrate that the decrease in cell viability was correlated
with decreased MET signaling.
ARQ 197 was also tested in a mouse xenograft model of myeloma.
Immunodeficient mice were injected subcutaneously with MM.1S
myeloma cells to generate xenograft tumors. These mice were treated
with ARQ 197 or vehicle using an established schedule that was
approved by UT MD Anderson Cancer Center Institutional Animal
Care andUseCommittee [17]. Themice were randomly placed in either
the vehicle treatment group or the ARQ197 treatment group (200mg/kg
per day × 5 days/week for 4 weeks). At the end of the treatment cycle,
tumors were excised and their volume was determined. Compared
with the vehicle-treated group (12 mice), the ARQ 197–treated group
(15mice) showedmedian lower tumor volume (Supplementary Figure 3).
Discussion
Myeloma was previously treated with steroids or with the DNA-dama-
ging agent melphalan. During the last decade, several novel agents that
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Figure 5. ARQ 197 inhibited the MET signaling pathway. (A) Immunoblot analysis of OPM-2 cells serum starved (0.1% FBS) for 24 hours
and treated with ARQ 197 for 6 hours, followed by stimulation with 50 ng/ml HGF for 15 minutes. (B) Immunoblot analysis of OPM-2 cells
serum starved (0.1% FBS) and treated with ARQ 197 for 24 hours, followed by stimulation with 50 ng/ml HGF for 15 minutes. (C) KAS-6/1
cells were serum starved for 8 hours, followed by treatment with ARQ 197 for 16 hours. Cells were stimulated with 50 ng/ml HGF and
examined by immunoblot analysis. A representative immunoblot from three biologic replicates is shown here. (D) KAS-6/R10R cells were
either serum starved (0.1% FBS) for 24 hours and treated with ARQ 197 for 16 hours or they were grown in 10% FBS and treated with
ARQ 197 for 24 hours. Serum-starved cells were further stimulated with 50 ng/ml HGF, and the cells were analyzed as in A. For each
immunoblot of this figure (A–D), only one GAPDH was needed because all proteins were done from the same gel and membrane by
cutting in several sections and using antibodies from different species. We use a fluorescence-based imaging system (LI-COR Odyssey
System) to analyze our immunoblots. With this system, our secondary antibodies against primary antibodies derived from different
species are tagged with different fluorescence colors.
296 Targeting MET in Multiple Myeloma Zaman et al. Neoplasia Vol. 17, No. 3, 2015impact the proteasomal degradation pathway such as bortezomib or
carfilzomib were approved as well as immunomodulatory agents such as
thalidomide or lenalidomide. These new agents, either as a single agent
or in combination, have now become the standard of care for MM.
While the therapeutic landscape has changed for this difficult disease,
none of the agents are targeted therapies.
Overproduction and expression of HGF have been established in
myeloma. This growth factor binds to the MET receptor tyrosine
kinase and this cassette propagates survival, migration, and
proliferation signals. High levels of HGF have been found in
myeloma patients’ plasma [3–6]. Studies from our group have
identified that HGF is overexpressed in primary myeloma plasma cells
[15]. Furthermore, genetic knockdown of this pathway or pharma-
cological inhibition impacted myeloma cell survival and proliferation.
However, genetic manipulation is not practical and previous small
molecule inhibitors are not clinically viable candidates.ARQ 197 is not only a potent inhibitor of MET kinase but is also
already in the clinics as an oral agent. Our present work focused on
testing this agent in the preclinical setting to demonstrate utility of
this compound for myeloma. Using a number of myeloma cell lines
(U266, MM.1S, OPM-2, RPMI-8226, ANBL-6, and KAS-6/1), we
demonstrated that ARQ 197 inhibited growth in a dose- and
time-dependent manner. Growth inhibition was associated with an
increase in apoptotic cells as observed by annexin/PI positivity and
PARP cleavage. Consistent with the cell line data, ARQ 197
treatment decreased phospho-MET(Y1234/1235) and total MET
levels in CD138+ plasma cells from patients with myeloma and
showed ARQ 197–mediated apoptosis.
Analysis of the HGF/MET signaling pathways in myeloma cell
lines demonstrated that ARQ 197 inhibited HGF-dependent
induction of phospho-MET. In addition, we observed a decrease in
total MET levels, which is consistent with earlier reports with cell
AB
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Figure 6. ARQ 197 treatment decreased viability of CD138+ cells frommyeloma patients and decreased phospho-MET(Y1234/1235) and
total MET levels. (A) CD138+ cells from 15 MM patients were treated with 0 or 10 μM ARQ 197 for 72 hours. Cells were stained with
annexin V and PI and analyzed by flow cytometry. The data are presented as the ratio of annexin V + PI positive cells in 10 μMARQ 197 to
0 μM ARQ 197 (**P b .05). (B) Primary bone marrow cells from three MM patients were treated with 0 or 10 μM ARQ 197 for 16 hours.
Cells were unstained (red) or stained for normal rabbit IgG (blue) or phospho-MET(Y1234/1235) (DMSO-treated cells in orange and ARQ
197-treated cells in green) and analyzed by flow cytometry after gating the cells for CD138 positivity. (C) Primary bone marrow cells from
three MM patients were treated as in B. Cells were unstained (red) or stained for normal mouse IgG (blue) or total MET (DMSO-treated
cells in orange and ARQ 197-treated cells in green) and analyzed by flow cytometry after gating the cells for CD138 positivity.
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decline might be due to ARQ 197–mediated ubiquitin-dependent
degradation of MET [20,36]. The decreases in phospho-MET and
total MET were associated with down-regulation of HGF/MET
effector pathways such as the AKT and MAPK pathways, which
control cell survival and proliferation.
Development of drug-induced cross-resistance is a common
phenomenon for myeloma. Hence, we tested drug-resistant myeloma
cell lines for biologic actions of ARQ 197. Melphalan and
glucocorticoids were once the standard of care for myeloma and are
still used in combination. Melphalan, an alkylating agent, has been
the mainstay for myeloma treatment since the 1960s. Myeloma
initially responds well to melphalan but quickly acquires resistance. A
major mechanism of melphalan resistance was through the
up-regulation of the Fanconi anemia/BRCA DNA damage repair
pathway, which results in repair of DNA damage induced by
melphalan [37]. We tested ARQ 197 against melphalan-sensitive
(8226/S) and melphalan-resistant (8226/LR-5) cell lines. 8226/LR-5cells have an IC50 of 20 μM for melphalan, which translates to a
seven-fold resistance to melphalan compared with the sensitive cell line
[26]. However, these cell lines were equally sensitive to ARQ 197.
Myeloma patients are also treated with glucocorticoids such as
dexamethasone, mostly in combination with other drugs. To examine
whether ARQ 197 is effective in cells that are glucocorticoid resistant,
we usedMM.1R cells [28,38,39]. This glucocorticoid-resistant cell line
has low expression as well as alternatively spliced isoforms of the
receptor and therefore does not undergo cytolysis upon binding of
glucocorticoids [38].We tested ARQ197 in this cell line andMM.1S, a
glucocorticoid-sensitive cell line. In both cell lines, cytotoxicity was
comparable, indicating that there was no cross-resistance.
During the last decade, immunomodulatory drugs such as thalidomide
and lenalidomide and proteasome inhibitors such as bortezomib and
carfilzomib have been introduced and approved for patients with
myeloma. Bortezomib is a proteasome inhibitor that induces apoptosis
in myeloma cells, in part by blocking the nuclear factor kappa-light-ch-
ain-enhancer of activated B cells pathway and stabilizing pro-apoptotic
298 Targeting MET in Multiple Myeloma Zaman et al. Neoplasia Vol. 17, No. 3, 2015proteins such as p53 and BAX and decreasing the levels of
anti-apoptotic proteins such as BCL-2 [40]. It has been approved as a
front-line single-agent therapy for myeloma. In combination with
conventional drugs for myeloma, bortezomib exhibits increased activity
against myeloma cells and has significantly improved patient survival.
We found that bortezomib-resistantmyeloma lines ANBL-6/V10R and
KAS-6/V10R were sensitive to ARQ 197.
Lenalidomide is a second-generation agent of thalidomide that has
been effective as a single agent in myeloma treatment since 2002 [41].
Lenalidomide has been shown to alter ubiquitination of Ikaros
transcription factors [42,43], which leads to numerous cellular and
immunomodulatory effects such as induction of apoptosis in
myeloma cells; decreased attachment of myeloma cells to the bone
marrow; decreased production of cytokines such as IL-6, vascular
endothelial growth factor, and tumor necrosis factor-α in the bone
marrow microenvironment; induction of caspase-8–dependent
apoptosis; blockage of angiogenesis; and stimulation natural killer
cells’ immunity against MM [41,44]. However, some MM patients
eventually become resistant to lenalidomide by activation of the Wnt/
β-catenin pathway [27] or overactivation of the HGF/MET pathway
(our unpublished data). Yet, in our current study, KAS-6/1 and
KAS-6/R10R cells were equally sensitive to ARQ 197. Collectively,
these data suggest that ARQ 197 ignores diverse mechanisms of
resistance induced by a variety of myeloma therapeutics.
In addition to developing drug-induced resistance mechanisms,
myeloma can acquire chemoresistance due to cell adhesion–mediated
drug resistance [35]. This phenomenon occurs due to interaction with
the bone marrow microenvironment that produces cytokines such as
IL-6, vascular endothelial growth factor, insulin-like growth factor-1,
and HGF, stimulating myeloma cell survival [1] However, our
investigations demonstrate that ARQ 197 overcomes the resistance
conferred by IL-6, HGF, or the bone marrow microenvironment.
In our study, ARQ 197 induced cell death in myeloma cell lines
and primary myeloma patient samples. Additionally, ARQ 197
treatment in a myeloma murine xenograft model showed median
lower tumor volume. While the efficacy in the xenograft model was
not dramatic as in the cell line models, the apparent difference could
be due to the establishment of xenografts using human myeloma
MM.1S cells. These cells are dependent on HGF stimulation for
activation of the MET signaling pathway. However, mouse HGF do
not activate human MET [45,46]. This would suggest that the
xenografts that formed developed independent of MET signaling, and
therefore, a MET kinase inhibitor would not be as effective in
reducing the tumor volume. This is supported by the observation that
there was heterogeneity in mice acquiring tumors. For both the
vehicle- and ARQ 197–treated groups, there was a wide variation in
the onset of tumors (from 4.4 to 15 weeks). Therefore, a heterogenic
feature of mice in acquiring tumors could have translated into
heterogeneity in their response rate.
In general, our current investigation support the notion that in
myeloma cell lines, ARQ 197 effectively inhibits MET phosphory-
lation, downregulates the MET signaling pathway, and induces
cytotoxicity. Our results are consistent with previous data where we
demonstrated that partially decreasing MET levels in myeloma cells
by stably transfecting a MET ribozyme construct increased the
therapeutic sensitivity of agents that further depleted MET levels
[12,13]. In concert, shRNA-mediated MET knockdown diminished
MET protein levels and induced apoptosis. Moreover, in our current
study, immunoblot analysis indicated that ARQ 197 inhibitedHGF-stimulated induction of phospho-MET in OPM-2 and KAS-6/
R10R cell lines. We observed approximately 50% inhibition of
phospho-MET at 300 nmol/l ARQ 197. This range of phospho-
MET inhibition is similar to that observed in solid tumors, for which
MET phosphorylation was inhibited by 100 to 300 nmol/l ARQ 197
[17]. Collectively, these data indicate that MET is a viable anti-cancer
target for myeloma treatment and that a MET inhibitor that works in
vivo will be effective in myeloma patients.
Our preclinical studies with ARQ 197 demonstrated that it
induced apoptosis in ex vivo models of myeloma. However, cell
apoptosis was induced in the presence of 10 μM concentration of the
drug. We note that at this concentration, ARQ 197 can target other
pathways. Recent studies have demonstrated that in addition to its
impact on the MET pathway, ARQ 197 also inhibits tubulin in lung
cancer cell lines [47,48]. The influence on tubulin resulted in cell
arrest in the G2/M phase of the cell cycle. Tivantinib reduced tubulin
polymerization in cells and in xenograft tumors by directly binding to
the colchicine binding site of tubulin [49]. We are now focusing on
the effect of ARQ 197 on tubulin and its biologic consequence in
myeloma cell lines.
In conclusion, we have demonstrated that inhibiting MET with
ARQ 197 induces apoptosis in myeloma cells. On the basis of these
data, we have initiated a phase II clinical trial of ARQ 197 in relapsed/
refractory myeloma (NCT01447914). This is a novel target-based
strategy that could lead to another drug for myeloma treatment.
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